Alerts

May the Microbiota of the long-lived Naked Mole-rat Affect Human Health?

Microbiota 2022 Speaker Prof. Dr. med. Gerd Birkenmeier

Porf.  Gerd Birkenmeier from University of Leipzig, Germany will join the Targeting Microbiota 2022 Congress and give a presentation entitled "May the Microbiota of the long-lived Naked Mole-rat Affect Human Health?.

Join Prof. Birkenmeier in Targeting Microbiota 2022 to benefit from his experience on the host - microbiota interactions.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Fecal Microbiota Transplantation as an Immunomodulatory and Anti-Infective Agent

Microbiota 2022 Congress speaker Jarosław BilinskDr. Jarosław Biliński, from Medical University of Warsaw, Poland will join the Targeting Microbiota 2022 Congress and give a presentation entitled "Fecal Microbiota Transplantation as an Immunomodulatory and Anti-Infective Agent".

There is mounting evidence that the gut microbiome directly influences immune responses, especially in patients with hematological malignancies undergoing hematopoietic cell transplantation. Recent studies show that fecal microbiota transplantation could decrease the number of infectious complications, decolonize the gut from antibiotic-resistant bacteria and even treat immune complications like graft-versus-host disease. More attention is paid to the prophylactic use of microbiota modulation in most affected patients, which could revolutionize current practices.

Join Dr. Biliński in Targeting Microbiota 2022 to benefit from his experience and better understand microbiota immunotherapy.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Gene Editing and Microbiome Therapy

Nahla MansourProf. Nahla Mansour, National Research Center, Egypt, will be joining us this October to discuss her latest findings on "Gene Editing and Microbiome Therapy". 

Gene editing holds a promising future in microbiome therapy and exploring the complex interplay between members of the microbiome and our bodies. 

In this presentation, Dr. Mansour will highlight the re-emerging of gene editing tools and multiple strategies in microbiome therapy past, present, and future. 

She will show her previous work describing the genetically engineered probiotic strains that have been constructed by our group and also our new project using CRISPR- Cas tools.

A whole session will be dedicated to the Strategies, Innovations & Challenges to Target Microbiota Dysbiosis.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Cancer therapy and Microbiota

Microbiota 2022 Congress speaker Maria Cecilia GironDr. Maria Cecilia Giron, from University of Padova, Italy will join the Targeting Microbiota 2022 Congress and give a presentation entitled "Cancer therapy and Microbiota".

Join Dr. Giron in Targeting Microbiota 2022 to benefit from his experience and better understand the role of microbiota in arterial thrombosis.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Interactions of Skin Microbiota with Chosen Plant Extracts and Natural Products

Microbiota 2022 Speakers 11Dr. Sebastian Granica, Medical University of Warsaw, Poland, will be joining the 9th ISM Annual Meeting to discuss the "Interactions of Skin Microbiota with Chosen Plant Extracts and Natural Products". 

Join Targeting Microbiota 2022 to lear more about the skin microbiota. Secure a place.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Gut Microbiome and Retinal Disorders: Recent Advances and Perspectives

Microbiota 2022 Speakers 9Dr. Dimitra Skondra, University of Chicago, USA, will be joining the 9th ISM Annual Meeting to discuss "Gut Microbiome and Retinal Disorders: Recent Advances and Perspectives".

Recent work demonstrates important role of gut microbiome and retinal diseases such as age-related macular degeneration and retinopathy of prematurity. Emerging evidence for the existence and pathways of gut-retina axis can elucidate previously unknown pathways involved in retinal diseases and also presents an exciting potential therapeutic avenue. This talk aims to provide an update on recent advances in the current knowledge on the relationship between the gut microbiome and retinal disorders.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

 

Vaginal Microbiota and Dysbiosis: Recent Advances and Perspective

Microbiota 2022 Speakers Gary VentoliniProf. Gary Ventolini, Texas Tech University Health Sciences Center, USA, will be joining the 9th ISM Annual Meeting to discuss the Recent Advances and Perspectives on Vaginal Microbiota and Dysbiosis. 

Trillions of bacteria colonize the human body and 9% are found in the female genital tract: vulva, vagina, cervix/uterus and adnexa. Vaginal microbiota influence from conception to birth has only been unbent during the last decade.

This presentation will appraise the vaginal microbiota, will review changes taking place during dysbiosis, and will update on current advances and outlooks regarding the impact on human reproduction. 

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Microbiota & Microbiotal Medicine: Where We are Now & What’s Next?

Microbiota 2022 Speakers 1

Dr. Marvin Edeas, Founder & Chairman of ISM, Institut Cochin, INSERM, Université de Paris, France, will introduce the 9th Targeting Microbiota meeting and he will talk about "Microbiota & Microbiotal Medicine: Where We are Now & What’s Next?".

The aim of Dr. Marvin Edeas is to introduce a new way of thinking about the medicine of tomorrow. He will initiate the reflection and discussion about strategies which will allow us to accelerate Microbiotal medicine.

Dr. Marvin Edeas will try to discuss:

- Why we failed to treat many diseases?

- Do we need to dedicate a specific treatment to one specific organ or specific pathology?

Dr. Marvin Edeas believes that the medicine of tomorrow will connect all organs together and with our microbiota and microbiome. All therapeutic strategies will come through the way we will take into consideration the quality of Microbiota and metabolites, signaling pathways, epigenetic and more.

Dr. Edeas thinks that we are still at the beginning in our exploration and we probably need to desiccate more the mechanism behind microbiota efficacy such as: extracellular vesicles and exosomes and their impact on microbiota communication and microbiota-host relationship, along with their potential implication in disease. Further explore the role of microbiota and its metabolites on iron metabolism should be highlighted.

He will discuss the 4 main axes that should be exploreed in the furture:

  1. Olfactory receptors;
  2. Brain and behaviour;
  3. Ageing & longevity;
  4. Artificial intelligence and algorithms.

 

Reference: Microbiota medicine: towards clinical revolution - BMC Journal of Translational Medicine

Join Targeting Microbiota 2022 to learn more about the future of microbiotal medicine.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

A Gut Commensal, Parabacteroides distasonis, and Type 1 Diabetes Onset

Targeting Microbiota 2022 Emrah AltindisDr. Emrah Altindis, from the Biology Department Boston College, USA, will be joining us this October to discuss his latest findings on the "A Gut Commensal, Parabacteroides distasonis, and Type 1 Diabetes Onset". 

Type 1 Diabetes (T1D) is an autoimmune disease characterized by the destruction of pancreatic β-cells. One of the earliest aspects of this process is development of autoantibodies and T-cells directed at an epitope in the B-chain of insulin (insB:9-23). Analysis of microbial protein sequences with homology to insB:9-23 sequence revealed 17 peptides showing >50% identity to insB:9-23. Of these, one peptide, found in the normal human gut commensal Parabacteroides distasonis, activated both human T cell clones from T1D patients and T-cell hybridomas from non-obese diabetic (NOD) mice specific to insB:9-23. Immunization of NOD mice with P. distasonis insB:9-23 peptide mimic or insB:9-23 peptide verified immune cross-reactivity. Colonization of female NOD mice with P. distasonis accelerated the development of T1D, increasing macrophages, dendritic cells and destructive CD8+ T-cells, while decreasing FoxP3+ regulatory T-cells. Western blot analysis identified P. distasonis reacting antibodies in sera of NOD mice colonized with P. distasonis and human T1D patients. Furthermore, adoptive transfer of splenocytes from P. distasonis treated mice to NOD/SCID mice enhanced disease phenotype in the recipients. Finally, analysis of human infant gut microbiome data revealed that exposure of infants to P. distasonis may modulate disease pathogenesis. Taken together, these data demonstrate the potential role for an insB:9-23-mimimetic peptide from gut microbiota as a molecular trigger or modifier of T1D pathogenesis.

Join Dr. Altindis in Targeting Microbiota 2022 to benefit from his experience and better understand the relationship between gut commensals and diabetes onset.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Influence of the Gut Microbiome in Ischemic Stroke Risk and Ischemic Stroke Outcome

Microbiota 2022 Speakers Miquel LledósDr. Miquel Lledós from the Biomedical Research Institute Sant Pau, Spain will join the Targeting Microbiota 2022 Congress and give a presentation entitled "Influence of the Gut Microbiome in Ischemic Stroke Risk and Ischemic Stroke Outcome".

We performed shotgun metagenomics sequencing to analyse the taxonomic profiles in ischemic stroke patients. We aimed to identify microbiota taxa associated with: risk of ischemic stroke, neurological outcome in the acute phase at 6h and 24h (classified with the National Institute of Health Stroke Scale (NIHSS) as mild, moderate or severe stroke), and functional outcome at 3 months measured with the modified Rankin Scale (mRS). We found multiple new taxonomic profiles associated with stroke, revealing that gut microbiome could be an important factor associated with stroke risk and stroke acute and long-term outcome.

Join Dr. Lledós in Targeting Microbiota 2022 to benefit from his experience and expand your knowledge about the link between the microbiota and stroke.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Interactions Between Epithelial Proteases And Gut Microbiota Biofilms During Intestinal Disease

Jean Paul Motta Microbiota 2022 Speakers 15Dr. Jean-Paul Motta, Institute of Digestive Health Research, France, will join Targeting Microbiota this October to present his new studies on the "Interactions Between Epithelial Proteases And Gut Microbiota Biofilms During Intestinal Disease". 

Dr. Motta states that Inflammatory Bowel Disease (IBD) is linked with abnormal upregulation of epithelial protease, such as elastase and thrombin. Their recent works aim to decipher the mechanisms by which such high protease activity could fuel intestinal inflammation via an action on host receptors, but also to directly alter commensal microbiota forming biofilms at the mucosal surface. 

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Host / Microbiota Interaction at the Mucosal Surface – Importance of a No Man’s Land !

Dr. Benoit ChassaingDr. Benoit Chassaing from Institut Cochin, France will join the Targeting Microbiota 2022 Congress and give a presentation entitled "Host / Microbiota Interaction at the Mucosal Surface – Importance of a No Man’s Land !".

Recent researches have highlighted the importance of a proper host-microbiota interaction at the mucosal surface, with the observation of microbiota encroachment within the normally sterile mucus layer in preclinical models of chronic inflammatory diseases as well as in humans suffering IBD or type 2 diabetes.

Dr. Chassaing's presentation will discuss dietary factors involved in the promotion of microbiota encroachment, as well as mechanisms by which targeted immunization can be used to prevent / reverse encroachment and hence protect against chronic inflammatory diseases.

Join Dr. Chassaing in Targeting Microbiota 2022 to benefit from his experience on the host - microbiota interactions.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Host-Microbes Mechanisms during E. coli Infections and Diet-induced Dysmetabolism

Microbiota 2022 Speakers

Dr. Matteo Serino, CRCN researcher from INSERM (France), will be joining us this October to present a talk entitled "Host-Microbes Mechanisms during E. coli Infections and Diet-induced Dysmetabolism".

A high-fat diet-induced gut microbiota dysbiosis is at the carrefour between E. coli infections and metabolic diseases such as obesity and type 2 diabetes. Dr. Serino will discuss about both cellular and molecular mechanisms governing dysbiosis-induced systemic, gut and hepatic inflammation in lean and obese mice.

These mechanisms include: i) platelets modulation as sentinels of E. coli-induced systemic inflammation; ii) NLRP3 inflammasome activation to control gut inflammation and iii) modulation of hepatic microRNAs as bridge molecules between gut microbes and hepatic inflammation.

Join us in Targeting Microbiota 2022 and benefit from the experience of Dr. Serino. Don't forget that you can share your work in this session by submitting your abstract.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Microbial Biomarkers to Predict Respiratory Infection

Microbiota 2022 Congress speaker Claire Woodal

Dr. Claire Woodall, a Daphne Jackson Fellow at the University of Bristol, will be presenting her research at the 9th ISM Annual Meeting to discuss “Microbial Biomarkers to Predict Respiratory Infection”.

Respiratory tract infections are the most common infections seen in primary care, and the single greatest contributor to the overall burden of infections worldwide. Community-acquired viral respiratory infection includes influenza-like illness and more recently, COVID-19 disease. Even in otherwise healthy adults, respiratory infections are common and they may experience multiple infections per year.

Microbial biomarker studies are proposed as an emerging tool to identify healthy adults most susceptible to respiratory infection. If this identification were possible, then alongside clinical primary care standard practice protective measures can be implemented early. This talk discusses the current evidence for microbial biomarkers predicting susceptibility to respiratory infection and asks the question: is the science there yet?

Join us in Targeting Microbiota 2022 and benefit from the experience of Dr. Woodall. Don't forget that you can share your work in this session by submitting your abstract.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Role of the Gut Microbiota in Arterial Thrombosis

Microbiota 2022 Dr. Christoph ReinhardtDr. Christoph Reinhardt, from University Mainz, Germany, will be joining us this October to discuss his latest findings on the "Role of the Gut Microbiota in Arterial Thrombosis". 

The gut microbiota impacts vascular phenotypes in the small intestinal mucosa but via the gut-liver axis also acts remotely on the hepatic sinusoidal endothelium.

Experimentation with germ-free mouse models indicates that this densely colonized microbial ecosystem promotes vascular inflammation and interferes with the atherosclerotic lesion development. Importantly, involving endothelial and platelet-dependent mechanisms, the gut microbiota promotes arterial thrombus growth.   

Join Dr. Christoph Reinhardt in Targeting Microbiota 2022 to benefit from his experience and better understand the role of microbiota in arterial thrombosis.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Oral Microbial Dysbiosis and Oral Diseases

Microbiota 2022 Dr. Xin XuDr. Xin Xu, from Sichuan University, China, will be joining us this October to discuss his latest findings on "Oral Microbial Dysbiosis and Oral Diseases". 

Dr. Xu's talk will discuss the microbial baseline in oral health, and oral diseases that are associated with microbial dysbiosis. Eocological approaches that aims to restore microbial ecology and thus rescue oral diseases will also be discussed.

Book your spot for Targeting Microbiota 2022 to benefit from Dr. Xu's experience and boost your knowledge on the oral microbiota.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Probiotics and FMT as Add-On Therapies for Depression

Dr André SchmidtDr. André Schmidt, from the University of Basel, Switzerland, will be joining us in October to discuss his latest findings on "Probiotics and FMT as Add-on Therapies for Depression". 

In fact, depression is a highly prevalent and burdensome psychiatric disorder. Even though antidepressants and further therapeutic approaches are widely applied, up to 30% of treatment-resistant patients experience residual symptoms when receiving optimized treatments. Therefore, the development of novel and more efficient treatment approaches is urgently needed. Compelling evidence shows that alterations in the gut microbiota composition impact human physiology and contribute to diseases including psychiatric disorders like depression. The manipulation of the gut microbiota as part of the microbiota-gut-brain (MGB) axis has emerged as promising new target for the treatment of depression.

In this talk, Dr. Schmidt presents data from a randomized controlled trial exploring clinical and biological effects along the MGB axis of probiotic supplementation in patients with depression. He further shows data from two depressed patients receiving fecal microbiota transplantation. These findings will be discussed in the view of current research and potential suggestions for future studies will be proposed aiming at developing microbial interventions for depression care.

Join Dr. Schmidt and other experts to know more about the "Strategies, Innovations & Challenges to Target Microbiota Dysbiosis".

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

The Probiotic Strain H. alvei HA4597 for Weight Loss

Dr Pierre DéchelotteIt is a great pleasure to welcome Dr. Pierre Déchelotte, from Rouen Normandy University, France during the 9th World Congress.

Dr. Déchelotte will present his most recent findings on The Probiotic Strain H. alvei HA4597 for Weight Loss, during the session dedicated to "Strategies, Innovations & Challenges to Target Microbiota Dysbiosis"

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Proof-of-Principle Demonstration of Endogenous Circadian System and Circadian Misalignment Effects on Human Oral Microbiota

Dr Frank ScheerDr. Frank Scheer, from Harvard Medical School, USA will be discussing his most recent findings on ''Proof-of-principle demonstration of endogenous circadian system and circadian misalignment effects on human oral microbiota''.

Shift workers are at increased risk for the development of diabetes, obesity, and cardiovascular disease. Dr. Scheer and colleagues have shown under highly-controlled human experimental protocols that circadian misalignment—the misalignment between the endogenous circadian system and the sleep/wake cycle—results in increases in inflammatory markers, elevated blood pressure, changes in hunger/appetite control, and impaired glucose tolerance; both in non-shift workers and in real-life shift workers. 

Since microbiota can play a key role in metabolism and inflammation, Dr. Scheer aimed to determine whether human oral microbiota (suitable for non-invasive and frequent repeat sampling): (1) express endogenous circadian rhythms (i.e., independent of sleep, eating, physical activity, and environmental light rhythms); and (2) are impacted by circadian misalignment.

In a proof-of-concept study, using highly-controlled 14-day in-laboratory experimental circadian studies, Dr. Scheer found that one of five dominant phyla and three of fourteen dominant genera exhibited endogenous circadian rhythms. Importantly, he found that four of the five dominant phyla and eight of the fourteen dominant genera were impacted by circadian misalignment. Furthermore, inferred gene content analysis indicated changes in specific functional pathways associated with metabolic control and immunity.

These findings may have relevance for the millions of shift workers, jet travelers, as well as the broader population when we change the timing of our sleep/wake cycles.

Additonal microbiota topics will be introduced during the Targeting Microbiota 2022 Congress, held this October - in Paris.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

 

Short-chain Fatty Acids as Modulators of Redox Signaling in Health and Disease

Dr Carmen González BoschDr. Carmen González-Bosch, from Universitat de València, Spain will be discussing her most recent findings on ''Short-chain Fatty Acids as Modulators of Redox Signaling in Health and Disease''.

It is now apparent that the microbiota is a critical determinant of human health and disease and a key regulator of host physiology. Several health benefits of specific food-derived molecules are related to their ability to activate antioxidant defences. Among these, is the well-studied isothiocyanate sulforaphane, found in cruciferous vegetables such as broccoli.

This protection occurs through activation of the Nuclear erythroid 2-related factor 2 (NRF2)-KEAP1 pathway, in which NRF2 serves as a master regulator of cellular antioxidant defences. Notably, short chain fatty acids, such as butyrate and propionate, produced by colonic bacteria and obtained from the diet, are also activators of NRF2, although studies on their role as regulators of redox homeostasis is limited.

Dr. González-Bosch recently critically reviewed this field, providing convincing evidence supporting their cytoprotective roles in suppressing inflammation and carcinogenesis and the consequences of aging.

The fact that phytochemicals, including sulforaphane, activate similar redox-sensitive genes in both plant and mammalian cells, prompted us to initiate a translational research project in collaboration with colleagues at King´s College of London with the objective of integrating knowledge from priming plants and mammalian cells based on redox homeostasis.

The design of improved experimental approaches to explore the mechanisms of production and action of SCFAs in cellular redox signaling under physiological oxygen levels will underpin strategies for developing personalized nutrition and therapeutics for redox medicine.

The Targeting Microbiota 2022 Congress, held this October - in Paris, will be hosting similar interesting topics on microbiota.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Manipulating Fiber Polysaccharide Structure to Alter Targeting to Gut Microbiota

Dr Stephen LindemannDr. Stephen Lindemann, from Purdue University, USA will be discussing his most recent findings on ''Manipulating Fiber Polysaccharide Structure to Alter Targeting to Gut Microbiota''.

Modulation of the gut microbiome’s composition and function using prebiotic fibers requires that individuals’ microbiota respond more similarly than idiosyncratically. Unfortunately, however, most common prebiotics are broadly utilized by diverse microbiota, and often fail in feeding trials to increase abundances of their targeted microbes. In contrast, however, arabinoxylans, which are hemicellulosic fibers from brans, elicit highly reproducible microbiome responses across individuals, both with respect to community structure and metabolic function. Fine differences in arabinoxylan structure make significant impacts on the most adapted microbial consortia. Furthermore, enzymatic pre-modification of arabinoxylan structure is able to retarget arabinoxylans to different microbial consumers, and their associated metabolites.

This talk will underscore the use of these complex fibers for predictable microbiome impact across diverse individual gut microbiomes. Join Dr. Lindemann during the Session entitled ''Strategies, Innovations & Challenges to Target Microbiota Dysbiosis'' to learn more about his talk.

More interesting topics on microbiota in nutrition will be presented during the Targeting Microbiota 2022 Congress, held this October - in Paris.

You can also submit your abstract for this session.

Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com

Microbiota in the Press & Media

  • 1
  • 2
  • 3
Prev Next